Tocilizumab Linked to High LDL, but not Cardiovascular Risk in RA
Tocilizumab may be associated with increasing LDL cholesterol in rheumatoid arthritis, but a new study shows that it is not associated with increased cardiovascular risk.
Choice of Second-Line Therapy in RA Influenced by MBDA Score
Rheumatoid arthritis patients with lower MBDA scores respond better to triple therapy vs. methotrexate and infliximab combo.
15 Recommendations for Treating Glucocorticoid-Induced Osteoporosis
For the first time in seven years, the ACR has new treatment recommendations for glucocorticoid-induced osteoporosis. In this slideshow, we highlight the new guidelines.
Moderate to Severe Chronic Pain May Signal Early Death
The severity of long-term chronic pain that impedes daily life seems to be associated with higher mortality, researchers report.
Adalimumab Biosimilar Performs Well in RA Trial
The biosimilar adalimumab-atto is equivalent to its reference product — which it slightly outperformed in this trial.
Biologics as First-Line Treatment in Early RA Proves Beneficial
This study is among the first to show that aggressive treatment of early rheumatoid arthritis with biologic DMARDs benefits high-risk patients.
JAK Inhibitor Peficitinib Reduces RA Symptoms
The orally administered once-daily peficitinib without concomitant use of methotrexate reduces symptoms of rheumatoid arthritis in trial.
By clicking Accept, you agree to become a member of the UBM Medica Community.